Markedsdata leveret af TwelveData og Morningstar
Nyxoah SA is a medical technology company focused on developing and commercializing solutions for obstructive sleep apnea, a common sleep-disordered breathing condition. Nyxoah’s lead product is the Genio system, a patient-centered hypoglossal neurostimulation therapy designed to help treat moderate to severe obstructive sleep apnea. The company operates in the healthcare equipment and neuromodulation space, serving a medical market that relies on minimally invasive technologies to address chronic respiratory and sleep-related disorders. Nyxoah SA is headquartered in Mont-Saint-Guibert, Belgium, and its current business centers on bringing sleep apnea treatment alternatives to clinical practice through its proprietary Genio platform.
Baseret på 4 analytikere